drugset
drugset / Trial / NCT01702909

Interleukin-2 in Metastatic Kidney Cancer

NCT01702909 ↗

Phase 2 Terminated 7 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.

Timeline

Start
2012-09
Primary completion
2014-12
Completion
2014-12

Outcome

Outcome not reported

Stopped: “PI Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — —

Indications

renal cell carcinoma